NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization75.81 mln
Float5.83 mln
Earnings Date08/06/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
34.83
Transformational upside
Relative Strength
42
/ 100
Slightly lagging
Debt / Equity
0.10
Very low leverage
ROE
-77.38
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Adicet Bio is a Boston-based biotech company focused on developing next-generation cell therapies for patients with autoimmune diseases and cancer. Its leading program uses donor-derived immune cells engineered to seek out and attack a specific protein found on harmful cells driving autoimmune conditions. The company is also advancing a second therapy aimed at a target commonly found in prostate cancer. Founded in 2014, Adicet Bio is currently running clinical trials to test the safety and effectiveness of these treatments.
